

## RUBRA MEDICAMENTS LIMITED

Part I					
(Rupees in Lacs)					
Statement of Standalone Unaudited Results for the Quarter and Year Ended 31/03/2015					
Sr. No	Particulars	For the Quarter Ended			For the Year Ended
		31-03-15	31-12-14	31-03-14	31-03-15
		Unaudited	Unaudited	Unaudited	Unaudited
1	Income from operations				
	Net Sales/Income from Operations (Net of Exccise Duty)	0.00	0.00	0.00	0.00
	Other Operating Income	0.00	0.00	0.00	0.00
	<b>Total Income from Operations (Net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
2	Expenses				
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00
b	Cost of Goods Traded	0.00	0.00	0.00	0.00
c	Employee Cost	0.42	0.00	0.00	0.42
d	Purchases of Stock-in-trade	0.00	0.00	0.00	0.00
e	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
f	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00
g	Other Expenses	1.10	1.61	1.59	7.06
	<b>Total Expenses</b>	<b>1.52</b>	<b>1.61</b>	<b>1.59</b>	<b>7.48</b>
3	<b>Profit / (Loss) from Ordinary activities before other income, finance costs and exceptional items (1-2)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
4	<b>Other Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
5	<b>Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
6	Finance Cost	0.00	0.00	0.00	0.00
7	<b>Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
8	Exceptional Items				
a)	Depletion of Assets	0.00	0.00	0.00	0.00
b)	Write Offs	0.00	0.00	0.00	0.00
	<b>Sub Total</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Profit / (Loss) from Ordinary activities before tax (7+8)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
10	Tax Expenses	0.00	0.00	0.00	0.00
11	<b>Profit / (Loss) from Ordinary activities after tax (9+10)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)</b>	<b>-1.52</b>	<b>-1.61</b>	<b>-1.59</b>	<b>-7.48</b>
17	Paid-up equity share capital (Face value of the Share is Re.10/- each)	54,683,000	54,683,000	54,683,000	54,683,000
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year				-200.27
19.i	Earnings Per Share (EPS) (before Extraordinary items) (not to be annualized)				
a)	Basic	0.00	0.00	0.00	0.00
b)	Diluted	0.00	0.00	0.00	0.00
19.ii	Earnings Per Share (EPS) (after Extraordinary items) (not to be annualized)				
a)	Basic	0.00	0.00	0.00	0.00
b)	Diluted	0.00	0.00	0.00	0.00

PART II					
Select Information for the quarter ended on March 31, 2015					
	Particulars	For the Quarter Ended			For the Year Ended
		31-03-15	31-12-14	31-03-14	31-03-15
A	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public shareholding				
	– Number of shares	5,465,300	5,465,300	5,465,300	5,465,300
	– Percentage of shareholding	99.95	99.95	99.95	99.95
2	Promoters and promoter group Shareholding **				
a)	Pledged/Encumbered				
	Number of shares	0	0	0	0
b)	Non-encumbered				
	Number of Shares	3000	3000	3000	3000
	Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	Percentage of shares (as a % of the total share capital of the company)	0.05	0.05	0.05	0.05

## Notes:

1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.
2	The Company has no segments.
3	The result is provisional and unaudited and subject to change, regrouping and restatement.
4	NIL Complaints were received during the quarter and NIL complaints were pending to be resolved at the end of the Quarter.
5	Due to the Resignaiton of the Statutory Auditors, the Financial Results for the Quarter and Year ended March 31, 2015 could not be Audited.

Date: May 25, 2015  
Place: Mumbai

For Rubra Medicaments Limited



**RUBRA MEDICAMENTS LIMITED**  
**STATEMENT OF ASSETS AND LIABILITIES**

A	EQUITY AND LIABILITIES		As on March 31, 2015	As on March 31, 2014
<b>1</b>	<b>Shareholders Funds</b>			
	(a)	Share Capital	54,683,000	54,683,000
	(b)	Reserves and Surplus	(50,026,952)	(20,026,952)
	(c)	Money received against share warrants	-	-
		<b>Sub-total - Shareholders' funds</b>	<b>4,656,048</b>	<b>34,656,048</b>
<b>2</b>	<b>Share application money pending allotment</b>			-
<b>3</b>	<b>Minority interest</b>			-
<b>4</b>	<b>Non-current liabilities</b>			
	(a)	Long-term borrowings	-	2,304,021
	(b)	Deferred tax liabilities (net)	-	746,257
	(c)	Other long-term liabilities	-	-
	(d)	Long-term provisions	-	-
		<b>Sub-total - Non-current liabilities</b>	<b>-</b>	<b>3,050,278</b>
<b>5</b>	<b>Current liabilities</b>			
	(a)	Short-term borrowings	-	-
	(b)	Trade payables	-	-
	(c)	Other current liabilities	-	49,510
	(d)	Short-term provisions	-	-
		<b>Sub-total - Current liabilities</b>	<b>-</b>	<b>49,510</b>
		<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>4,656,048</b>	<b>37,755,836</b>
<b>B</b>	<b>ASSETS</b>			
<b>1</b>	<b>Non-current assets</b>			
	(a)	Fixed assets	-	-
	(b)	Goodwill on consolidation	-	-
	(c)	Non-current investments	-	-
	(d)	Deferred tax assets (net)	-	-
	(e)	Long-term loans and advances	3,054,070	33,054,070
	(f)	Other non-current assets	168,819	168,819
		<b>Sub-total - Non-current assets</b>	<b>3,222,889</b>	<b>33,222,889</b>
<b>2</b>	<b>Current Assets</b>			
	(a)	Current investments	-	-
	(b)	Inventories	-	-
	(c)	Trade receivables	177,269	177,269
	(d)	Cash and Bank Balance	1,255,890	4,355,678
	(e)	Short-term loans and advances	-	-
	(f)	Other current assets	-	-
		<b>Sub-total - Current assets</b>	<b>1,433,159</b>	<b>4,532,947</b>
		<b>TOTAL - ASSETS</b>	<b>4,656,048</b>	<b>37,755,836</b>

